H.P. Acthar Gel
Chronic Migraine
Dent Neuroscience Research Centerprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Chronic Migraine cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin Taipei Veterans General Hospital, Taiwan | Phase 4 | BB |
Galcanezumab Beth Israel Deaconess Medical Center | Phase 4 | BB |
Onabotulinum Toxin A University of Alberta | Phase 4 | BB |
BETAMETHASONE Jakob Møller Hansen, MD. | Phase 4 | BB |
Fremanezumab Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | B |
View all 15 →
Same molecule, other indications
H.P. Acthar Gel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →